caa a22 4500 469121661 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246258 doi (NATIONALLICENCE)springer-10.1007/BF02246258 Use of moclobemide in children with attention deficit hyperactivity disorder [Elektronische Daten] [G. Trott, H. Friese, M. Menzel, G. Nissen] A monoamine oxidase hypothesis for the cause of attention deficit hyperactivity disorder has recently been established (Shekim et al. 1986). To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study. All had previously discontinued treatment with methylphenidate due to side-effects. A 40% improvement in parental assessment of children's behaviour occurred among those who received moclobemide as outpatients, and a 31% improvement among the five in-patients. There was a general increase in concentration and attention span at the end of the trial, but mood changes and explosive behaviour continued to be present at a low level. Brain mapping after moclobemide treatment showed an overall reduction in frontal lobe delta activity. Moclobemide was well tolerated by these patients, although two complained of mild gastrointestinal disturbances during the first week of therapy. Springer-Verlag, 1992 Moclobemide nationallicence Monoamine oxidase inhibitor nationallicence Hyperkinetic syndrome nationallicence Attention deficit hyperactivity disorder nationallicence Trott G. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut Friese H. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut Menzel M. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut Nissen G. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut Psychopharmacology Springer-Verlag 106(1992-02-01), S134-S136 0033-3158 106<S134 1992 106 213 https://doi.org/10.1007/BF02246258 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246258 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Trott G. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut NATIONALLICENCE 700 1- Friese H. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut NATIONALLICENCE 700 1- Menzel M. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut NATIONALLICENCE 700 1- Nissen G. Hospital for Child and Adolescent Psychiatry, University of Würzburg, Füchsleinstrasse 15, W-8700, Würzburg, Germany aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S134-S136 0033-3158 106<S134 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer